|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.090 USD | +9.42% |
|
-7.11% | -65.06% |
| 11-12 | BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| 11-12 | BioXcel Therapeutics Q3 revenue misses analyst expectations | RE |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
Biological Products | |||||||||
Pharmaceuticals | - | - | 375K | 1.38M | 2.27M | ||||
Total Assets | 220M | 239M | 206M | 73.7M | 38.34M | ||||
Interest Expense | -27K | -40K | -8.21M | -13.31M | -15.13M | ||||
CAPEX | -316K | -445K | -139K | -20K | - | ||||
EBT | -82.17M | -107M | -166M | -179M | -59.6M | ||||
D&A | 188K | 297K | 327K | 318K | 309K | ||||
Operating Income | -82.3M | -107M | -160M | -172M | -67.24M | ||||
Net Income | -82.17M | -107M | -166M | -179M | -59.6M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
United States | - | - | 375K | 1.38M | 2.27M | ||||
Total Assets | 220M | 239M | 206M | 73.7M | 38.34M | ||||
Interest Expense | -27K | -40K | -8.21M | -13.31M | -15.13M | ||||
D&A | 188K | 297K | 327K | 318K | 309K | ||||
CAPEX | -316K | -445K | -139K | -20K | - | ||||
Net Income | -82.17M | -107M | -166M | -179M | -59.6M | ||||
EBT | -82.17M | -107M | -166M | -179M | -59.6M | ||||
Operating Income | -82.3M | -107M | -160M | -172M | -67.24M |
- Stock Market
- Equities
- BTAI Stock
- Financials BioXcel Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition